Newron Pharmaceuticals S.p.A.
Biopharmaceutical company developing therapies for nervous system disorders and pain.
NWRN | SW
Overview
Corporate Details
- ISIN(s):
- IT0004147952
- LEI:
- 8156002F8C11F80A9740
- Country:
- Italy
- Address:
- VIA MEUCCI, 3, 20091 BRESSO
- Website:
- https://www.newron.com/
- Sector:
- Manufacturing
Description
Newron Pharmaceuticals is a biopharmaceutical company focused on the research and development of novel therapies for diseases of the central and peripheral nervous system (CNS) and pain. The company's portfolio includes Xadago® (safinamide), a globally partnered treatment for Parkinson's disease. Its clinical-stage pipeline is centered on CNS disorders, with a key candidate, evenamide, under investigation for the treatment of schizophrenia.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-03-14 01:00 |
EQS-News: Newron enters into an agreement for the subscription of up to 2.05 m…
|
English | 13.4 KB | ||
| 2024-03-14 01:00 |
EQS-News: Newron: Zeichnungsvereinbarung über bis zu 2,05 Millionen neu ausgege…
|
German | 13.6 KB | ||
| 2024-03-14 01:00 |
EQS-Adhoc: Newron: Zeichnungsvereinbarung über bis zu 2,05 Millionen neu ausgeg…
|
English | 11.9 KB | ||
| 2024-01-12 01:00 |
EQS-PVR: Newron Pharmaceuticals S.p.A.: Veröffentlichung gemäß § 40 Abs. 1 WpHG…
|
German | 10.0 KB | ||
| 2024-01-04 01:00 |
EQS-News: Newron reports exceptional one-year results of study 014/15 with even…
|
English | 19.1 KB | ||
| 2024-01-04 01:00 |
EQS-News: Newron berichtet herausragende Einjahres-Ergebnisse der Studie 014/15…
|
German | 22.1 KB | ||
| 2024-01-04 01:00 |
EQS-Adhoc: Newron berichtet positive Einjahres-Ergebnisse der Studie 014/15 mit…
|
German | 15.9 KB | ||
| 2023-12-29 01:00 |
EQS-Adhoc: Newron schließt Rekrutierung von Schizophrenie-Patienten für potenzi…
|
German | 10.9 KB | ||
| 2023-12-29 01:00 |
EQS-News: Newron completes enrollment of schizophrenia patients in potentially…
|
English | 9.5 KB | ||
| 2023-12-29 01:00 |
EQS-News: Newron schließt Rekrutierung von Schizophrenie-Patienten für potenzie…
|
German | 10.8 KB | ||
| 2023-10-09 02:00 |
EQS-News: Newron TRS study 6 months’ results: Evenamide substantially improves …
|
English | 15.7 KB | ||
| 2023-10-09 02:00 |
EQS-News: Newron TRS-Studie, 6-Monatsergebnisse: Evenamide verbessert Patiente…
|
German | 18.7 KB | ||
| 2023-10-09 02:00 |
EQS-Adhoc: Newron TRS-Studie, 6-Monatsergebnisse: Evenamide verbessert Patient…
|
German | 15.0 KB | ||
| 2023-10-04 02:00 |
EQS-News: Newron to present three posters on its clinical program evaluating ev…
|
English | 10.4 KB | ||
| 2023-10-04 02:00 |
EQS-News: Newron präsentiert drei Poster zum klinischen Entwicklungs-Programm m…
|
German | 11.6 KB |
Automate Your Workflow. Get a real-time feed of all Newron Pharmaceuticals S.p.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Newron Pharmaceuticals S.p.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Newron Pharmaceuticals S.p.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
